Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mark G. Frattini
Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Strategy for Incorporating Molecular and Cytogenetic Markers Into Acute Myeloid Leukemia Therapy
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Related publications
Enasidenib-Induced Eosinophilic Differentiation in a Patient With Acute Myeloid Leukaemia With IDH2 and U2AF1 Mutations
British Journal of Haematology
Hematology
Combination Treatment of an IDH1 Inhibitor With Chemotherapy in IDH1 Mutant Acute Myeloid Leukemia
Annals of Hematology
Medicine
Hematology
Challenges in Treating Older Patients With Acute Myeloid Leukemia
Journal of Oncology
Oncology
How I Treat Older Patients With Acute Myeloid Leukemia
Cancer
Cancer Research
Oncology
Enasidenib in Acute Myeloid Leukemia: Clinical Development and Perspectives on Treatment
Cancer Management and Research
Oncology
Acute Myeloid Leukemia in Patients Older Than 60 Year
Journal of Tumor Medicine & Prevention
Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Decitabine Compared With Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness
Advances in Hematology
Hematology
Healthcare Resource Utilization in a Phase 3 Study of CPX-351 in Patients With Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia
Journal of Medical Economics
Health Policy
